JOURNAL OF BACTERIOLOGY AND VIROLOGY ISSN:1598-2467(Print) 2093-0429(Online)

Principi N, Silvestri E, Esposito S. Advantages and limitations of bacteriophages for the treatment of bacterial infections. Front Pharmacol. 2019;10:513.

Helen EW, Elena VO. Bacteriophages: Their structural organisation and function. In: Renos S, editor. Bacteriophages. IntechOpen; 2019.

Onsea J, Post V, Buchholz T, Schwegler H, Zeiter S, Wagemans J, et al. Bacteriophage therapy for the prevention and treatment of fracture-related infection caused by Staphylococcus aureus: a preclinical study. Microbiol Spectr. 2021;9(3):e0173621.

Mursalin MH, Astley R, Coburn PS, Bagaruka E, Hunt JJ, Fischetti VA, et al. Therapeutic potential of Bacillus phage lysin PlyB in ocular infections. mSphere. 2023;8(4):e0004423.

Al-Anany AM, Hooey PB, Cook JD, Burrows LL, Martyniuk J, Hynes AP, et al. Phage therapy in the management of urinary tract infections: A comprehensive systematic review. Phage (New Rochelle). 2023;4(3):112-127.

Gao Z, Feng Y. Bacteriophage strategies for overcoming host antiviral immunity. Front Microbiol. 2023;14:1211793.

Dowah ASA, Clokie MRJ. Review of the nature, diversity and structure of bacteriophage receptor binding proteins that target Gram-positive bacteria. Biophys Rev. 2018;10(2):535-542.

Elois MA, Silva RD, Pilati GVT, Rodríguez-Lázaro D, Fongaro G. Bacteriophages as biotechnological tools. Viruses. 2023;15(2):349.

Yang Q, Le S, Zhu T, Wu N. Regulations of phage therapy across the world. Front Microbiol. 2023;14:1250848.

The promise of phages. Nat Biotechnol. 2023;41(5):583.

Global Bacteriophage Market Insights. Available at https://www.skyquestt.com/report/ bacteriophage-market#:~:text=Bacteriophage%20Market%20size%20was%20valued,period%20(2023%2D2030). [accessed on 18 March 2024].

Lin DM, Koskella B, Lin HC. Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J Gastrointest Pharmacol Ther. 2017 Aug 6;8(3):162-173.

Loc-Carrillo C, Abedon ST. Pros and cons of phage therapy. Bacteriophage. 2011;1(2):111-114.

Oechslin F. Resistance development to bacteriophages occurring during bacteriophage therapy. Viruses. 2018;10(7):351.

Hyman P. Phages for phage therapy: Isolation, characterization, and host range breadth. Pharmaceuticals (Basel). 2019;12(1):35.

Denissen J, Reyneke B, Waso-Reyneke M, Havenga B, Barnard T, Khan S, et al. Prevalence of ESKAPE pathogens in the environment: Antibiotic resistance status, community-acquired infection and risk to human health. Int J Hygiene Environ Health. 2022;244:114006.

Bai H, Graham C. Introduction: Skin. Yale J Biol Med. 2020;93(1):1-2.

Wang J, Meng W, Zhang K, Wang J, Lu B, Wang R, et al. Topically applied bacteriophage to control multi-drug resistant Pseudomonas aeruginosa-infected wounds in a New Zealand rabbit model. Front Microbiol. 2022;13:1031101.

Kielholz T, Rohde F, Jung N, Windbergs M. Bacteriophage-loaded functional nanofibers for treatment of P. aeruginosa and S. aureus wound infections. Sci Rep. 2023;13(1):8330.

Kiladze N, Chanishvili N, Shulaia T, Bendeliani Z, Zaichenko Y. Phages in Treatment of Some Deep Purulent Skin Infections. Lviv clinical bulletin. 2017;3(19):39-43.

Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666-667.

Köhler T, Luscher A, Falconnet L, Resch G, McBride R, Mai QA, et al. Personalized aerosolised bacteriophage treatment of a chronic lung infection due to multidrug-resistant Pseudomonas aeruginosa. Nat Commun. 2023;14(1):3629.

Pabary R, Singh C, Morales S, Bush A, Alshafi K, Bilton D, et al. Antipseudomonal Bacteriophage Reduces Infective Burden and Inflammatory Response in Murine Lung. Antimicrob Agents Chemother. 2016;60(2):744-751.

Fauroux B, Hart N, Belfar S, Boulé M, Tillous-Borde I, Bonnet D, et al. Burkholderia cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients. J Clin Microbiol. 2004 42(12):5537-5541.

Zuppi M, Hendrickson HL, O'Sullivan JM, Vatanen T. Phages in the Gut Ecosystem. Front Cell infect microbiol. 2022;11:822562.

Gutiérrez B, Domingo-Calap P. Phage therapy in gastrointestinal diseases. Microorganisms. 2020;8(9):1420.

Shuwen H, Kefeng D. Intestinal phages interact with bacteria and are involved in human diseases. Gut microbes. 2022;14(1):2113717.

Emencheta SC, Olovo CV, Eze OC, Kalu CF, Berebon DP, Onuigbo EB, et al. The role of bacteriophages in the gut microbiota: Implications for human health. Pharmaceutics. 2023;15(10):2416.

Available at https://www.mountsinai.org/about/newsroom/2018/fda-oks-clinical-trial-to-test-bacteriophagebased-treatment-for-crohns-carolina-henriques [accessed on 20 February 2018].

Pradal I, Casado A, del Rio B, Rodriguez-Lucas C, Fernandez M, Alvarez MA, et al. Enterococcus faecium bacteriophage vB_EfaH_163, a new member of the herelleviridae family, reduces the mortality associated with an E. faecium vanR clinical isolate in a Galleria mellonella animal model. Viruses. 2023;15(1):179.

Song M, Wu D, Hu Y, Luo H, Li G. Characterization of an Enterococcus faecalis bacteriophage vB_EfaM_LG1 and its synergistic effect with antibiotic. Front CellInfect Microbiol. 2021;11:698807.

LaVergne S, Hamilton T, Biswas B, Kumaraswamy M, Schooley RT, Wooten D. Phage therapy for a multidrug-resistant Acinetobacter baumannii craniectomy site infection. Open forum Infect Dis. 2018;5(4):ofy064.

Ichikawa M, Nakamoto N, Kredo-Russo S, Weinstock E, Weiner IN, Khabra E, et al. Bacteriophage therapy against pathological Klebsiella pneumoniae ameliorates the course of primary sclerosing cholangitis. Nat Commun. 2023;14(1):3261.

Waters EM, Neill DR, Kaman B, Sahota JS, Clokie MRJ, Winstanley C, et al. Phage therapy is highly effective against chronic lung infections with Pseudomonas aeruginosa. Thorax. 2017;72(7):666-667.

Zalewska-Piątek B, Piątek R. Phage Therapy as a novel strategy in the treatment of urinary tract infections caused by E. Coli. Antibiotics (Basel). 2020;9(6):304.

Bhargava K, Nath G, Dhameja N, Kumar R, Aseri GK, Jain N. Bacteriophage therapy for Escherichia coli-induced urinary tract infection in rats. Future Microbiol. 2023;18:323-334.

Møller-Olsen C, Ho SFS, Shukla RD, Feher T, Sagona AP. Engineered K1F bacteriophages kill intracellular Escherichia coli K1 in human epithelial cells. Sci Rep. 2018;8(1):17559.

Nikkhahi F, Soltan Dallal MM, Alimohammadi M, Rahimi Foroushani A, Rajabi Z. Fardsanei F, et al. Phage therapy: assessment of the efficacy of a bacteriophage isolated in the treatment of salmonellosis induced by Salmonella enteritidis in mice. Gastroenterol Hepatol Bed Bench. 2017;10(2):131-136.

Scholl D, Rogers S, Adhya S, Merril CR. Bacteriophage K1-5 encodes two different tail fiber proteins, allowing it to infect and replicate on both K1 and K5 strains of Escherichia coli. J Virol. 2001;75(6):2509-2515.

Rosner D, Clark J. Formulations for bacteriophage therapy and the potential uses of immobilization. Pharmaceuticals (Basel). 2021;14(4):359.

Flint R, Laucirica DR, Chan HK, Chang BJ, Stick SM, Kicic A. Stability considerations for bacteriophages in liquid formulations designed for nebulization. Cells. 2023;12(16):2057.

Manohar P, Ramesh N. Improved lyophilization conditions for long-term storage of bacteriophages. Sci Rep. 2019;9(1):15242.

Vázquez R, Díez-Martínez R, Domingo-Calap P, García P, Gutiérrez D, Muniesa M, et al. Essential topics for the regulatory consideration of phages as clinically valuable therapeutic agents: A perspective from spain. Microorganisms. 2022;10(4):717.

Huang Y, Wang W, Zhang Z, Gu Y, Huang A, Wang J, et al. Phage products for fighting antimicrobial resistance. Microorganisms. 2022;10(7):1324.

Soffer N, Abuladze T, Woolston J. Li M, Hanna LF, Heyse S, et al. Bacteriophages safely reduce Salmonella contamination in pet food and raw pet food ingredients. Bacteriophage. 2016;6(3):e1220347.

Moye ZD, Woolston J, Sulakvelidze A. Bacteriophage applications for food production and processing. Viruses. 2018;10(4):205.

Chung KM, Liau XL, Tang SS. Bacteriophages and their host range in multidrug-resistant bacterial disease treatment. Pharmaceuticals (Basel). 2023;16(10):1467.

Wdowiak M, Paczesny J, Raza S. Enhancing the stability of bacteriophages using physical, chemical, and nano-based approaches: A review. Pharmaceutics. 2022;14(9):1936.

Labrie SJ, Samson JE, Moineau S. Bacteriophage resistance mechanisms. Nat Rev Microbiol. 2010;8(5):317-327.

Ranveer SA, Dasriya V, Ahmad MF, Dhillon HS, Samtiya M, Shama E, et al. Positive and negative aspects of bacteriophages and their immense role in the food chain. NPJ Sci Food. 2024;8(1):1.

Suleman M, Clark JR, Bull S, Jones JD. Ethical argument for establishing good manufacturing practice for phage therapy in the UK. J Med Ethics. 2024;jme-2023-109423.

Tanir T, Orellana M, Escalante A, Moraes de Souza C, Koeris MS. Manufacturing bacteriophages: Cell line development, upstream, and downstream considerations. Pharmaceuticals (Basel). 2021;14(9):934.